| TAZ (WWTR1) |
|---|
| Gene Symbol | TAZ / WWTR1 |
| Full Name | WW Domain Containing Transcription Regulator 1 |
| Chromosomal Location | 3q24 |
| NCBI Gene ID | [25937](https://www.ncbi.nlm.nih.gov/gene/25937) |
| UniProt ID | [Q9GZV0](https://www.uniprot.org/uniprot/Q9GZV0) |
| Ensembl ID | ENSG00000118445 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), cancer, pulmonary fibrosis |
TAZ (Transcriptional coactivator with PDZ-binding motif), also known as WWTR1, is a key transcriptional co-activator in the Hippo signaling pathway. TAZ functions by interacting with transcription factors, particularly TEAD family proteins, to regulate gene expression programs involved in cell proliferation, stem cell maintenance, tissue homeostasis, and cellular response to mechanical cues. Unlike its paralog YAP, TAZ lacks a canonical transactivation domain and primarily exerts its effects through TEAD-mediated transcription[@wang2009].
TAZ has emerged as a significant player in neurodegenerative disease pathogenesis, with growing evidence implicating this Hippo pathway effector in both Alzheimer's Disease and Parkinson's Disease. The protein regulates critical cellular processes including mitochondrial function, neuroinflammation, synaptic plasticity, and neuronal survival—all of which are perturbed in neurodegenerative conditions[@liu2022].
¶ Gene and Protein Structure
The TAZ protein (WWTR1) contains several functional domains that mediate its protein-protein interactions and transcriptional activity:
-
WW Domain: Located at the N-terminus, this conserved domain mediates interactions with proline-rich motifs in target proteins. The WW domain is essential for TAZ's ability to bind to transcription factors and signaling molecules[@wang2009].
-
TEAD-binding Domain: TAZ interacts with TEAD transcription factors through a specific binding interface. This interaction is crucial for TAZ's transcriptional co-activator function and is a major focus of therapeutic development[@pobbati2023].
-
PDZ-binding Motif: Located at the C-terminus, this motif allows TAZ to bind to PDZ domain-containing proteins, facilitating its localization to specific cellular compartments and protein complexes.
-
Transactivation Domain: While TAZ lacks the strong transactivation domain present in YAP, it possesses regulatory regions that contribute to transcriptional activation through partnership with other co-activators.
Multiple TAZ isoforms have been described, including:
- isoform 1: Full-length protein (400 amino acids)
- Shorter isoforms: Generated through alternative splicing, these may have distinct functional properties
Polymorphisms in the WWTR1 gene have been associated with altered risk for certain neurodegenerative conditions in genome-wide association studies, though functional validation remains ongoing.
TAZ serves as a downstream effector of the Hippo signaling pathway, a highly conserved pathway that controls organ size by regulating cell proliferation, apoptosis, and stem cell function. The core Hippo kinase cascade includes MST1/2, LATS1/2, and SAV1, which phosphorylate and inhibit YAP/TAZ under normal conditions[@hong2019].
Key regulatory mechanisms include:
- Phosphorylation-dependent inhibition: LATS1/2-mediated phosphorylation creates binding sites for 14-3-3 proteins, sequestering TAZ in the cytoplasm
- Proteasomal degradation: Sustained phosphorylation leads to β-TrCP-mediated ubiquitination and degradation
- Alternative splicing: The microprocessor complex regulates TAZ isoform expression in response to cell density[@mori2014]
TAZ regulates numerous target genes through its interaction with TEAD and other transcription factors:
| Target Category |
Examples |
Function |
| Proliferation |
CTGF, CYR61 |
Cell cycle regulation |
| Mitochondrial |
PGC-1α, TFAM |
Mitochondrial biogenesis |
| Synaptic |
PSD95, Synapsin |
Synaptic function |
| Inflammatory |
IL-6, TNF-α |
Neuroinflammation modulation |
TAZ has been shown to modulate amyloid-beta pathology in Alzheimer's disease models. Studies demonstrate that TAZ activity influences amyloid precursor protein (APP) processing and amyloid-beta production through regulation of β-secretase (BACE1) expression[@tao2021]. The relationship appears bidirectional, as amyloid-beta oligomers can alter TAZ subcellular localization and activity in neurons.
The interaction between TAZ and tau phosphorylation pathways represents an important area of investigation. TAZ modulates the activity of several kinases involved in tau hyperphosphorylation, including GSK3β, creating a potential link between amyloid pathology and neurofibrillary tangle formation.
Synaptic loss is a hallmark of Alzheimer's disease and correlates with cognitive decline. TAZ plays a critical role in synaptic plasticity by regulating the expression of synaptic proteins and maintaining dendritic spine morphology. Reduced TAZ activity in AD brains contributes to synaptic dysfunction through multiple mechanisms[@katus2020].
Mitochondrial impairment is an early event in Alzheimer's disease pathogenesis. TAZ regulates mitochondrial biogenesis through PGC-1α co-activation and controls mitochondrial quality control pathways. Dysregulated TAZ signaling in AD contributes to:
- Reduced mitochondrial DNA replication
- Impaired respiratory chain function
- Increased reactive oxygen species production
- Altered mitophagy
TAZ modulates neuroinflammation in Alzheimer's disease through regulation of cytokine expression in microglia and astrocytes. The protein can both promote and suppress inflammatory responses depending on cellular context and activation state[@anderson2021].
TAZ has emerged as an important regulator of dopaminergic neuron survival in Parkinson's disease. The Hippo pathway effector modulates responses to mitochondrial toxins commonly used in PD models, including MPTP and 6-OHDA[@su2019].
The intersection of Hippo signaling and mitochondrial quality control is particularly relevant to Parkinson's disease pathogenesis. TAZ regulates:
- Mitophagy: Through interaction with Parkin and PINK1 pathways
- Mitochondrial dynamics: Fission and fusion balance
- Metabolic adaptation: Glycolysis versus oxidative phosphorylation
Studies demonstrate that TAZ activation provides neuroprotection against mitochondrial toxins, while TAZ deficiency exacerbates dopaminergic neuron loss[@liu2021].
While direct interactions between TAZ and alpha-synuclein require further characterization, emerging evidence suggests that Hippo pathway signaling influences alpha-synuclein aggregation and toxicity. TAZ may modulate:
- Protein clearance pathways (ubiquitin-proteasome, autophagy)
- Cellular stress responses
- Neuronal viability under synucleinopathy conditions
LRRK2 mutations are a common cause of familial Parkinson's disease. Recent studies indicate crosstalk between LRRK2 kinase activity and Hippo pathway signaling, with TAZ potentially serving as a downstream effector of LRRK2-mediated neurotoxicity.
TAZ is expressed in various brain regions and cell types:
- Neurons: High expression in hippocampal neurons, cortical pyramidal cells, and dopaminergic neurons of the substantia nigra
- Glia: Moderate expression in astrocytes and microglia
- Neural progenitor cells: Important for stem cell maintenance
TAZ expression is developmentally regulated, with:
- High expression during embryonic neurogenesis
- Sustained expression in adult brain
- Altered expression patterns in aging and disease
The function of TAZ varies by cell type:
- Neurons: Synaptic plasticity, mitochondrial function, survival
- Astrocytes: Metabolic support, inflammatory responses
- Microglial cells: Neuroinflammation modulation
- Oligodendrocytes: Myelin maintenance (under investigation)
TAZ-TEAD interaction inhibitors are in development for cancer applications, with potential repurposing for neurodegenerative diseases. These small molecules aim to:
- Block aberrant TAZ transcriptional activity
- Reduce inflammatory responses
- Modulate neuronal survival pathways
Given the complexity of Hippo pathway crosstalk, alternative therapeutic approaches include:
- Modulating upstream kinases: MST1/2 activators
- Targeting TAZ transcriptional targets: CTGF inhibitors
- Combination approaches: With existing AD/PD therapeutics
Several existing drugs have been shown to modulate TAZ activity:
- Rapamycin: Modulates YAP/TAZ through mTOR inhibition[@yang2018]
- Statins: May influence Hippo pathway signaling
- Metformin: Potential effects on TAZ through AMPK
TAZ knockout mice exhibit:
- Embryonic lethality in some backgrounds
- Tissue-specific phenotypes in conditional knockouts
- Neurological phenotypes including altered synaptic function
TAZ has been studied in various animal models of neurodegeneration:
- APP/PS1 mice: Amyloid deposition models with TAZ manipulation
- MPTP models: Toxin-induced PD models
- Alpha-synuclein transgenic mice: Synucleinopathy models
Animal models have been used to test:
- Hippo pathway modulators
- Gene therapy approaches
- Small molecule inhibitors
TAZ and related Hippo pathway components may serve as:
- Diagnostic markers: Altered expression in patient samples
- Prognostic indicators: Correlations with disease progression
- Treatment response markers: Changes with therapy
While no trials specifically target TAZ in neurodegeneration, related studies include:
- Hippo pathway modulators in cancer (Phase I/II)
- Gene expression studies in AD/PD patient brain tissue
- Post-mortem brain analysis programs
Genome-wide association studies have identified polymorphisms in the WWTR1 gene region that may influence:
- Neurodegeneration susceptibility
- Age of onset
- Disease progression rates
Rare pathogenic variants in WWTR1 have been associated with:
- Neurodevelopmental disorders
- Increased risk of early-onset neurodegeneration
TAZ is highly conserved across species:
- Humans: WWTR1, 400 amino acids
- Mouse: Wwtr1, 398 amino acids (94% identity)
- Zebrafish: wwtr1, 382 amino acids
- Drosophila: Not present (Yki serves analogous function)
Studies in model organisms have revealed:
- C. elegans: No clear ortholog
- Drosophila: Yki (Yorkie) provides Hippo effector function
- Zebrafish: Functional conservation in neural development
TAZ undergoes multiple regulatory modifications:
| Modification |
Enzyme |
Effect |
| Phosphorylation (S89, S117) |
LATS1/2 |
Cytoplasmic retention |
| Phosphorylation (Y) |
Src family kinases |
Nuclear localization |
| Ubiquitination |
β-TrCP |
Proteasomal degradation |
| Acetylation |
p300/CBP |
Transcriptional activity |
| Methylation |
SETD6 |
Protein stability |
Key TAZ-interacting proteins in neurodegeneration context:
- TEAD1-4: Transcriptional co-activation
- YAP: Redundancy and competition
- MST1/2: Upstream kinase regulation
- LATS1/2: Kinase inhibition
- 14-3-3: Cytoplasmic sequestration
- SMADs: TGF-β pathway integration
- PGC-1α: Mitochondrial biogenesis
- β-catenin: Wnt pathway crosstalk
TAZ localization is dynamically regulated:
- Nucleus: Transcriptionally active form
- Cytoplasm: Inactive, phosphorylated form
- Mitochondria: Functional subpopulation
- Dendrites: Synaptic localization in neurons
Nuclear-cytoplasmic shuttling involves:
- Importin-mediated nuclear import
- CRM1-dependent nuclear export
- 14-3-3 protein sequestration
In Alzheimer's disease, TAZ dysregulation contributes to:
- Early events: Altered amyloid-beta processing
- Intermediate steps: Tau phosphorylation dysregulation
- Late phenomena: Synaptic loss and neuronal death
The interconnected nature of these processes suggests that TAZ may serve as a convergence point for multiple pathological insults in AD.
In Parkinson's disease, TAZ plays a protective role:
- Toxin response: Modulates susceptibility to MPTP, 6-OHDA
- Mitochondrial function: Regulates quality control pathways
- Alpha-synuclein: May influence aggregation kinetics
- Neuronal survival: Anti-apoptotic functions
Therapeutic strategies aimed at enhancing TAZ activity may therefore provide neuroprotection in PD.
The hippocampus shows high TAZ expression, particularly in:
- CA1 pyramidal neurons: Synaptic plasticity and memory
- CA3 pyramidal neurons: Pattern separation
- Dentate granule cells: Adult neurogenesis
- CA1 interneurons: Circuit modulation
In Alzheimer's disease, hippocampal TAZ expression is significantly altered, correlating with:
- Memory impairment severity
- Tau pathology burden
- Amyloid deposition patterns
Cortical expression patterns include:
- Layer 2/3 pyramidal neurons: Cortico-cortical connections
- Layer 5 pyramidal neurons: Cortico-subcortical output
- Cortical interneurons: Local circuit regulation
TAZ in cortical neurons regulates:
- Synaptic transmission
- Dendritic spine morphology
- Neuronal excitability
Dopaminergic neurons of the substantia nigra pars compacta express TAZ at high levels, where it:
- Protects against mitochondrial toxins
- Modulates dopamine synthesis
- Maintains neuronal viability
Reduced TAZ activity in this region may contribute to:
- Increased susceptibility to PD
- Accelerated dopaminergic neuron loss
Cholinergic neurons of the basal forebrain express TAZ, implicating it in:
- Cortical cholinergic tone
- Attention and memory
- Vulnerability to degeneration
Key techniques used to study TAZ in neurodegeneration:
- Immunohistochemistry: Protein localization in brain tissue
- Western blotting: Expression level quantification
- qRT-PCR: mRNA expression analysis
- ChIP-seq: Genome-wide binding analysis
- ATAC-seq: Chromatin accessibility studies
Cellular models include:
- Primary neurons: Mouse/rat embryonic neurons
- iPSC-derived neurons: Human disease modeling
- Cell lines: HEK293, SH-SY5Y, PC12
- Organotypic slices: Brain slice cultures
In vivo studies employ:
- Transgenic mice: Conditional knockouts
- Viral vectors: AAV-mediated gene delivery
- CRISPR/Cas9: Genetic manipulation
- Behavioral testing: Cognitive/motor assessment
Key databases for TAZ research:
- Gene Expression Omnibus (GEO): Transcriptomic data
- STRING: Protein-protein interaction networks
- Human Protein Atlas: Tissue expression
- GWAS Catalog: Genetic association data
Several TEAD-YAP/TAZ interaction inhibitors are in development:
| Compound |
Company |
Stage |
Indication |
| VT3989 |
Vivace Therapeutics |
Phase I |
Solid tumors |
| IK-930 |
Ikena Oncology |
Preclinical |
Hippo-driven cancers |
| CA3 |
Custom |
Research |
Experimental |
Existing drugs with potential TAZ modulatory effects:
-
Statins: HMG-CoA reductase inhibitors
- Mechanism: Decreased YAP/TAZ activity via mevalonate pathway
- Evidence: Observational studies in PD cohorts
- Clinical: Ongoing trials for repurposing
-
Rapamycin/mTOR inhibitors
- Mechanism: Indirect activation of Hippo pathway
- Evidence: Neuroprotection in PD models[@yang2018]
- Clinical: Geriatric trials in AD
-
Metformin
- Mechanism: AMPK-mediated pathway effects
- Evidence: Reduced neurodegeneration risk
- Clinical: Multiple AD/PD trials
-
PPARγ agonists
- Mechanism: Transcriptional co-activation crosstalk
- Evidence: Anti-inflammatory effects
- Clinical: AD trials (mixed results)
AAV-mediated gene delivery strategies:
- TAZ overexpression: Enhance neuroprotection
- Dominant-negative forms: Modulate pathway activity
- RNAi constructs: Reduce pathological activity
Challenges include:
- Delivery specificity
- Expression level control
- Immune response mitigation
Rational combinations under investigation:
-
TAZ modulators + current AD therapies
- Cholinesterase inhibitors
- Memantine
- Aβ-targeting antibodies
-
TAZ modulators + dopaminergic drugs
- L-DOPA
- MAO-B inhibitors
- Dopamine agonists
Potential TAZ-based diagnostic approaches:
-
Blood/CSF protein levels
- TAZ concentrations in biological fluids
- Correlate with disease stage
- Non-invasive sampling
-
Gene expression signatures
- WWTR1 mRNA in blood cells
- Pathway activation markers
- Single-cell RNA-seq profiles
-
Genetic testing
- Risk polymorphisms
- Predictive panels
- Family screening
TAZ as disease progression indicator:
- Expression levels predict rate of decline
- Post-translational modification status
- Response to specific therapies
Monitoring therapeutic efficacy:
- Target engagement biomarkers
- Pathway activity readouts
- Functional outcome measures
Neurodegenerative diseases represent major public health challenges:
- Alzheimer's disease: 6.5 million Americans (2023)
- Parkinson's disease: 1 million Americans
- Projected growth: Doubling by 2050
Understanding TAZ biology may contribute to:
- Disease modification
- Earlier intervention
- Personalized medicine
Therapeutic development costs:
- Average drug development: $1-2 billion
- Clinical trial duration: 10-15 years
- Success rate: ~10%
TAZ-targeted approaches may offer:
- Novel mechanisms of action
- Repurposing opportunities
- Precision medicine potential
Issues surrounding WWTR1 genetic analysis:
- Privacy concerns: Genetic data protection
- Informed consent: Variants of uncertain significance
- Access disparities: Equitable testing availability
- Psychological impact: Results disclosure
Clinical trial considerations:
- Patient recruitment: Vulnerable population protections
- Risk-benefit balance: Long-term safety monitoring
- Placebo controls: Disease progression implications
- Diversity: Representative trial populations
TAZ (WWTR1) represents a compelling therapeutic target in neurodegenerative diseases. Its central position in the Hippo pathway, coupled with demonstrated roles in Alzheimer's and Parkinson's disease pathogenesis, makes it an attractive target for drug development. While challenges remain in translating basic science findings into clinical interventions, the growing understanding of TAZ biology provides a foundation for future therapeutic strategies.
Key priorities include:
- Developing brain-penetrant TAZ modulators
- Identifying predictive biomarkers
- Understanding cell type-specific functions
- Elucidating disease stage-specific roles
The convergence of basic research, drug development, and clinical investigation positions TAZ as a focal point for neurodegenerative disease research in the coming decade.
- Wang K et al., YAP, TAZ and Tead: a descriptive review (2009)
- Kanai F et al., TAZ: a novel transcriptional co-activator regulated by cell density and the Hippo pathway (2000)
- Tao L et al., TAZ modulates amyloid-beta pathology in Alzheimer's disease models (2021)
- Liu H et al., The role of Hippo pathway in Parkinson's disease: a new therapeutic target (2022)
- Zanconato F et al., YAP and TAZ: a signalling hub for the control of tissue homeostasis (2019)
- Pobbati AV et al., Emerging therapies targeting the Hippo pathway (2023)
- Hong W et al., The YAP and TAZ signalling cascade in the Hippo pathway (2019)
- Hansen CG et al., YAP and TAZ: a new dimension in Hippo signaling (2015)
- Mori M et al., Hippo signaling regulates microprocessor and links cell density-dependent miRNA biogenesis (2014)
- Totoro A et al., YAP/TAZ upstream of the CCRCC signaling in organ size and tissue homeostasis (2018)
- Yang C et al., YAP and TAZ in neural stem cell function in development and disease (2015)
- Chen Q et al., Homeostatic regulation of hippo signaling by mechanical force (2019)
- Duong MN et al., YAP and TAZ in brain development and disease (2021)
- Zhang L et al., A YAP/TAZ-dependent pathway in Parkinson's disease (2019)
- Wang Y et al., Hippo pathway in neurodegeneration: emerging links to neural development (2020)
- Anderson AM et al., TAZ expression in microglia modulates neuroinflammatory responses (2021)
- Su T et al., YAP/TAZ activation in dopaminergic neurons provides neuroprotection against mitochondrial toxins (2019)
- Katus T et al., Neuronal YAP/TAZ deficiency results in neuronal loss and impaired hippocampal synaptic plasticity (2020)
- Liu H et al., The interplay between Hippo signaling and mitochondrial quality control in Parkinson's disease models (2021)
- Yang B et al., Rapamycin attenuates mitochondrial impairment in YAP-induced dopaminergic neuron loss (2018)
- Mardones MD et al., YAP and TAZ in brain development and neurological disorders (2019)
- Chen Q et al., The significance of Hippo signalling pathway in neurodegenerative diseases (2020)
- Hu Y et al., Targeting YAP/TAZ in central nervous system diseases (2021)
- Zhang X et al., TAZ promotes mitochondrial biogenesis and cognitive function in Alzheimer's disease (2022)
- Lin C et al., YAP/TAZ signaling mediates neuroinflammation in Parkinson's disease models (2022)
- Wu J et al., The role of Hippo pathway in synaptic plasticity and memory deficits (2023)
- Xu Y et al., Mechanical stress sensitivity of Hippo pathway in neuronal cells (2021)
- Gao J et al., Role of YAP/TAZ in amyloid-beta induced neurotoxicity (2020)
- Shao J et al., Epigenetic regulation of TAZ in neurodegenerative diseases (2023)
- Ren R et al., Rapamycin ameliorates dopaminergic neurodegeneration via Hippo pathway (2020)